$1.71
+0.07 (+4.27%)
Open$1.64
Previous Close$1.64
Day High$1.75
Day Low$1.59
52W High$3.82
52W Low$0.56
Volume—
Avg Volume1.26M
Market Cap59.28M
P/E Ratio—
EPS$-1.26
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+728.1% upside
Current
$1.71
$1.71
Target
$14.16
$14.16
$9.87
$14.16 avg
$18.59
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.37M | 2.29M | 19.24M |
| Net Income | -62,882,260 | -94,797,376 | -3,136,016 |
| Profit Margin | -4,594.3% | -4,364.5% | -16.3% |
| EBITDA | -61,068,073 | -97,177,000 | -4,591,050 |
| Free Cash Flow | — | — | -2,958,449 |
| Rev Growth | -40.3% | -40.3% | -5.9% |
| Debt/Equity | 0.91 | 0.91 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |